ORIGINAL ARTICLE
Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database

EH Allott1,2,3, MR Abern1, L Gerber1, CJ Keto1, WJ Aronson4,5, MK Terri6,7, CJ Kane8, CL Amling9, MR Cooperberg10, PG Moorman11 and SJ Freedland1,3,12

BACKGROUND: While epidemiologic studies suggest that metformin use among diabetics may decrease prostate cancer (PC) incidence, the effect of metformin use on PC outcome is unclear. We investigated the association between pre-operative metformin use, dose and duration of use and biochemical recurrence (BCR) in PC patients with diabetes who underwent radical prostatectomy (RP).

METHODS: We conducted a retrospective cohort analysis within the Shared Equal Access Regional Cancer Hospital (SEARCH) database of 371 PC patients with diabetes who underwent RP. Time to BCR between metformin users and non-users, and by metformin dose and duration of use was assessed using multivariable Cox proportional analysis adjusted for demographic, clinical and/or pathologic features. Time to castrate-resistant PC (CRPC), metastases and PC-specific mortality were explored as secondary outcomes using unadjusted analyses.

RESULTS: Of 371 diabetic men, 156 (42%) were using metformin before RP. Metformin use was associated with more recent year of surgery (P < 0.0001) but no clinical or pathologic characteristics. After adjustment for year of surgery, clinical and pathologic features, there were no associations between metformin use (hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.61–1.41), high metformin dose (HR 0.96; 95% CI 0.57–1.61) or duration of use (HR 1.00; 95% CI 0.99–1.02) and time to BCR. A total of 14 patients (3.8%) developed CRPC, 10 (2.7%) distant metastases and 8 (2.2%) died from PC. Unadjusted analysis suggested that high metformin dose vs non-use was associated with increased risk of CRPC (HR 5.1; 95% CI 1.6–16.5), metastases (HR 4.8; 95% CI 1.2–18.5) and PC-specific mortality (HR 5.0; 95% CI 1.1–22.5).

CONCLUSIONS: Metformin use, dose or duration of use was not associated with BCR in this cohort of diabetic PC patients treated with RP. The suggestion that higher metformin dose was associated with increased risk of CRPC, metastases and PC-specific mortality merits testing in large prospective studies with longer follow-up.

INTRODUCTION
Prostate cancer (PC) is the second most commonly diagnosed cancer in men with nearly 1 000 000 new cases per year worldwide.1 Prevalence of type II diabetes is rising, and is estimated to affect ~10% of men in westernized society.2 Meta-analyses have found diabetes to be associated with 14–21% decreased overall PC incidence, and subgroup analyses have demonstrated a temporal association between diabetes and decreased PC risk, with significant protective effect seen only in men with diabetes longer than 5 years.3,4 It has therefore been hypothesized that the metabolic and hormonal environment of advanced/end-stage diabetes, characterized by reduced bioavailable testosterone levels and a hypoinsulinemic state, is consistent with protection from overall PC incidence.

Metformin, a first-line therapy for type II diabetes, is associated with reduced overall cancer incidence5–8 and decreased cancer-specific mortality among individuals with diabetes, relative to either sulfonylurea or insulin use.9,10 In PC, pre-clinical studies have shown that metformin can exert direct anti-proliferative effects on PC cells both in vitro and in vivo via a variety of mechanisms including cell-cycle arrest,11 mTOR inhibition via AMPK-independent mechanisms12 and in addition to growth inhibition via AMPK-dependent mechanisms.13 In addition, since elevated systemic insulin levels pre-PC diagnosis (using C-peptide as a surrogate) have been associated with PC mortality,14 it is possible that the systemic insulin-lowering properties of metformin may also contribute to protection against PC progression.

1Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA; 2Section of Urology, Veterans Affairs Medical Center, Durham, NC, USA; 3Urology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA; 4Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA; 5Section of Urology, Veterans Affairs Medical Center, Augusta, GA, USA; 6Section of Urology, Medical College of Georgia, Augusta, GA, USA; 7Department of Urology, University of California, San Diego, San Diego, CA, USA; 8Division of Urology, Oregon Health Sciences University, Portland, OR, USA; 9Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; 10Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA and 11Department of Pathology, Duke University School of Medicine, Durham, NC, USA.

Correspondence: Dr SJ Freedland, Division of Urologic Surgery, Department of Surgery, Duke University School of Medicine, Box 2626, Durham, NC 27710, USA.
E-mail: steve.freedland@duke.edu

Received 3 July 2013; revised 5 September 2013; accepted 9 September 2013; published online 8 October 2013
To date, four observational studies have specifically addressed the effect of metformin on PC risk in humans. One population-based case–control study found metformin use to be associated with a borderline significant 44% decrease in PC incidence in diabetics (odds ratio (OR) 0.56; 95% confidence interval (CI) 0.32–1.00), while another found metformin use to reduce PC risk by 20% (OR 0.80; 95% CI 0.73–0.88). On the contrary, both a cohort study and a nested case–control study reported a lack of association between metformin therapy and PC risk in diabetic patients. Regarding PC-specific outcomes, to our knowledge only three retrospective cohort studies have been published to date. One examined 210 diabetic patients, 112 of whom were taking metformin, and found no effect of metformin use risk of biochemical recurrence (BCR) following radical prostatectomy (RP). These null findings were subsequently replicated in a larger study of 885 RP patients with diabetes, 323 of whom were taking metformin, which found no effect on BCR, metastases or overall survival. Another examined 319 diabetic patients who underwent external beam radiation therapy for localized PC, 157 of whom were taking metformin, and found metformin use to be associated with significantly reduced risk of BCR, castrate-resistant PC (CRPC), distant metastasis and PC-specific mortality. To our knowledge, no studies have examined the effect of metformin dose or duration of use on PC outcomes.

Given these conflicting results regarding the association between metformin and PC outcomes, we sought to test whether metformin use, dose and duration of use was associated with outcomes among diabetic men undergoing RP using the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Given epidemiologic and biological evidence suggesting anti-tumorigenic properties of metformin, we hypothesized that metformin use would be associated with more favorable pathologic features and reduced risk of BCR following RP relative to diabetic patients not taking metformin.

MATERIALS AND METHODS

Study population
After obtaining institutional review board approval from each institution, data from patients undergoing RP between 1988 and 2010 at four VA Medical Centers (West Los Angeles, CA; Durham, NC; Asheville, NC; and Augusta, GA) were combined into SEARCH. SEARCH does not include data from patients undergoing RP between 1988 and 2010 at four VA facilities in Augusta, GA and College Station, TX, USA.

Exposure assessment and definitions
Pre-operative metformin use was assessed by examining the metformin use at the time of surgery. Metformin dose at the time of surgery and the earliest use date (from which duration of use in months was calculated) was ascertained by examining the pharmacy database within the VA computerized medical records, and was available for all metformin users.

Follow-up
Follow-up protocols were left to the discretion of the treating physicians. BCR was defined as a single PSA of >0.2 ng ml\(^{-1}\), two consecutive concentrations at 0.2 ng ml\(^{-1}\), or secondary treatment for dose-dense or post-operative PSA. Men receiving adjuvant therapy ≤6 months after surgery for an undetectable PSA were considered as non-recurrent at the time of adjuvant therapy, and their follow-up was censored at that point for BCR, but continued for long-term outcomes. Distant metastases, defined as bone, visceral or distant adenopathy (not pelvic adenopathy), were determined by review of radionuclide bone scans, magnetic resonance imaging scans, computed tomography scans, plain radiograph reports and clinical progress notes. Decision to perform radiographic imaging was at the treating physician’s discretion. CRPC was defined using Prostate Cancer Working Group two criteria: 25% PSA increase from the androgen deprivation therapy PSA nadir and PSA increase ≥2 ng ml\(^{-1}\). PC-specific mortality was defined as death in any patient with metastases showing PC progression following androgen deprivation therapy.

Statistical analysis

Differences in demographic, clinical and pathologic factors between metformin users and non-users were examined using t-tests and \(\chi^2\) tests for continuous and categorical variables, respectively, and rank-sum tests for continuous variables not normally distributed. For examining distribution of clinicopathological features across metformin doses, we used ANOVA, \(\chi^2\) and Kruskal–Wallis as appropriate.

Multivariable logistic regression analysis was used to test whether metformin use was associated with pathological Gleason score (<7 vs ≥7), extracapsular extension, seminal vesicle invasion and positive margins. There were insufficient numbers of men (n = 2) with positive lymph nodes to examine this pathologic feature. The influence of metformin dose (available for all metformin users) on pathologic features and BCR was modeled using daily metformin dose as a three tier categorical variable (≤2000 mg day\(^{-1}\) low; >2000 mg day\(^{-1}\) high; n = 73); vs 0 mg that is, metformin non-use). We examined the effect of duration of metformin use (measured in months) on pathologic features and BCR using the earliest date of metformin (continuous; available for all metformin users). Logistic regression models were adjusted for age at surgery (continuous), year of surgery (continuous), body mass index (BMI) (continuous), race (black, non-black), pre-operative PSA (continuous, natural log-transformed), surgical center (categorical), biopsy Gleason score (2–6, 7) and clinical stage (T1 vs T2/T3).

Time from RP to BCR (primary outcome) and time to CRPC, metastases and PC-specific death (secondary outcomes) were compared between metformin users and non-users using Kaplan–Meier plots and the log-rank test. With a cohort of 371 patients, we had 80% power to detect a hazard ratio (HR) of <0.75 or >1.33 for metformin use and risk of BCR, using a two-sided alpha of <0.05. Cox proportional hazards models were used to test whether metformin use independently predicted time to these events.

For our primary outcome of BCR, we adjusted for clinical factors (age at surgery, year of surgery, BMI, race, pre-operative PSA, surgical center, biopsy Gleason score and clinical stage). As secondary analysis, we adjusted for aforementioned clinical factors (dropping biopsy Gleason), in addition to pathologic factors (pathologic Gleason score (2–6, 7, 8–10), extracapsular extension, seminal vesicle invasion and positive margins (all categorical)). In addition, we examined the association of metformin dose and duration of use with risk of the various outcomes, adjusting for aforementioned clinical and pathologic features. For secondary outcomes, time to CRPC-specific death and PC-specific death, the small numbers of events precluded multivariable analysis and so clinical and pathologic variables were added to our models one at a time, and results were treated as exploratory.

Statistical analysis was performed using Stata, version 11.0 (Stata Corp, College Station, TX, USA).

RESULTS

Among all 371 diabetic men, 156 (42%) were using metformin at the time of surgery (Table 1). Metformin users were more recently treated compared with non-users (P = 0.0001), resulting in significantly shorter follow-up for metformin users (59 vs 73 months, P = 0.004). The number of biopsy cores sampled and duration of diabetes significantly differed between users and non-users, but there were no other significant differences in demographic or clinical characteristics between metformin users and non-users. Percentage glycosylated hemoglobin (HbA1c) in the year before surgery, a measure of diabetes control, was available for 293 men (79%) and did not differ between metformin users and non-users (P = 0.425) (Table 1). High metformin dose was significantly associated with increased HbA1c levels (P = 0.02) and increased seminal vesicle invasion (P = 0.023), but was unrelated to other clinical or pathological characteristics (Table 2). On multivariable analysis, there were no associations...
between metformin use, dose or duration of use and adverse pathologic features in this cohort (Table 3). Adjusting our analyses for duration of diabetes and HbA1c levels did not alter our results (data not shown).

Of 371 diabetic patients, 134 (36%) progressed to BCR. Of metformin users, 49 (31%) recurred and 85 (40%) of metformin non-users recurred. Median follow-up among men who did not recur was 65 months (interquartile range: 40–96). We analyzed crude risk of BCR in diabetic patients, comparing metformin users and non-users. Metformin use was not significantly associated with risk of BCR in crude analysis (HR 0.86, 95% CI 0.61–1.23, Figure 1), or following adjustment for clinical features (HR 1.01, 95% CI 0.67–1.52), or following adjustment for both clinical and pathologic features (HR 0.93, 95% CI 0.61–1.41; Table 4). Furthermore, there was no association of metformin dose or months of use with risk of BCR on crude or adjusted analyses (Figure 1, Table 4). Adjusting our analyses for duration of diabetes and HbA1c levels did not alter our results (data not shown).

We assessed the association between metformin use, duration of use, and dose with longer term outcomes of CRPC, distant metastasis and PC-specific mortality. A total of 14 patients (3.8%) developed CRPC, 10 (2.7%) distant metastases and 8 (2.2%) died from PC. On unadjusted analysis, metformin use was unrelated to metastases or PC-specific mortality, however, metformin use was associated with borderline increased risk of CRPC (Table 5; \( P = 0.054 \)). While duration of metformin use did not show any association with any longer term outcomes, there were suggestions that high metformin dose (\( \geq 2000 \text{ mg} \)) vs no metformin) was associated with increased risk of distant outcomes including CRPC (HR 5.1; 95% CI 1.6–16.5; \( P = 0.006 \)), distant metastases (HR 4.8; 95% CI 1.23–18.5; \( P = 0.024 \)) and PC-specific mortality (HR 4.97; 95% CI 1.10–22.5; \( P = 0.037 \)), with no significant associations at

### Table 1. Demographic, clinical and pathological features of metformin users and non-users

| Metformin use pre-surgery | No (n = 215) | Yes (n = 156) | \( P^a \) |
|---------------------------|-------------|--------------|--------|
| Age at surgery, mean (s.d.) | 62.2 (5.8)  | 61.6 (5.8)  | 0.292\(^b\) |
| Months follow-up, median (IQR) | 73 (45–110) | 59 (37–81)  | 0.004\(^d\) |
| Race, n (%) | | | |
| White | 98 (45.6) | 77 (49.4) | 0.475\(^d\) |
| Black | 103 (47.9) | 73 (46.8) | |
| Other | 14 (6.5) | 6 (3.9) | |
| Year of surgery, median (IQR) | 2002 (1998–2006) | 2005 (2003–2007) | <0.0001\(^d\) |
| BMI (kg m\(^{-2}\)), n (%) | | | |
| \(< 24.9 | 24 (12.8) | 15 (9.8) | 0.565\(^d\) |
| 25.0–29.9 | 76 (40.6) | 69 (45.1) | |
| 30.0–34.9 | 63 (33.7) | 45 (29.4) | |
| \( \geq 35.0 | 24 (12.8) | 24 (15.7) | |
| Duration of diabetes (months), median (IQR) | 37 (10–86) | 52 (26–97) | 0.004\(^d\) |
| Duration metformin use (months), median (IQR) | NA | 26 (11–45) | NA |
| % HbA1c, median (IQR) | 6.8 (6.2–8.0) | 7.1 (6.1–8.1) | 0.425\(^d\) |
| Pre-operative PSA, median (IQR) | 6.5 (4.7–10.2) | 5.7 (4.7–8.3) | 0.106\(^d\) |
| Biopsy Gleason sum, n (%) | | | |
| 2–6 | 119 (55.9) | 79 (51.3) | 0.687\(^d\) |
| 7 | 70 (32.9) | 56 (36.4) | |
| 8–10 | 24 (11.3) | 19 (12.3) | |
| Clinical stage, n (%) | | | |
| T1 | 131 (67.2) | 104 (69.8) | 0.605\(^d\) |
| T2/T3 | 64 (32.8) | 45 (30.2) | |
| Total biopsy cores, n (%) | 9 (7–11) | 10 (8–12) | 0.019 |
| % Positive cores, median (IQR) | 25 (16.7–50.0) | 33 (16.7–57.7) | 0.127\(^d\) |
| Prostate weight, median (IQR) | 37.6 (29.4–50.0) | 39 (30.0–50.5) | 0.436\(^d\) |
| Pathologic Gleason sum, n (%) | | | |
| 2–6 | 68 (31.8) | 44 (28.2) | |
| 7 | 120 (56.1) | 87 (55.8) | |
| 8–10 | 26 (12.2) | 25 (16.0) | 0.505\(^d\) |
| Positive surgical margins, n (%) | 97 (45.1) | 73 (46.8) | 0.749\(^d\) |
| Seminal vesicle invasion, n (%) | 23 (10.7) | 13 (8.4) | 0.459\(^d\) |
| Extracapsular extension, n (%) | 39 (18.1) | 33 (21.7) | 0.396\(^d\) |
| Lymph-node metastases, n (%) | 1 (0.5) | 1 (0.6) | 0.881\(^d\) |

Abbreviations: BMI, body mass index; HbA1c, glycosylated hemoglobin; IQR, interquartile range.

\(^a\)P-values computed using t test, \(^w\)2 and rank sum.

\(^b\)P-values computed using t test.

\(^c\)P-values computed using rank sum.

\(^d\)P-values computed using \( \chi^2 \).

Bold indicates significant \( P \) value (\( P < 0.05 \)).
Metformin use and prostate cancer recurrence

In this cohort of diabetic PC patients, there was no effect of metformin use, dose or duration of use on adverse pathologic features or time to BCR. Three retrospective cohort studies previously examined the effect of metformin use on PC-specific outcomes. Similar to our own study, Patel et al. found no associations between metformin use and BCR or pathologic outcome in RP patients. In a larger but otherwise similar retrospective cohort study of 323 metformin users and 562 non-users, Kaushik et al. found no associations between metformin use and BCR, adverse pathology, metastasis or overall survival. Our null findings regarding metformin use and BCR are in agreement with both of these prior studies. Spratt et al. examined the effect of metformin use on BCR and long-term outcomes after external beam radiation therapy for localized PC. In contrast to our analysis, and that of these prior studies, Spratt et al. reported a significant reduction in risk of BCR, development of CRPC, distant metastases and PC-specific mortality in metformin users vs non-users. Of note, this study reported an extremely large HR of 5.15 (95% CI 1.53–17.35) for metformin non-use on PC-specific mortality which, viewed alternatively, corresponds to an HR of 0.19 for metformin use. For purposes of comparison, two randomized trials of RP vs watchful waiting showed that RP reduced PC-specific mortality by ~40%. Therefore, this study suggested that metformin use is approximately twice as effective as RP for reducing PC-specific mortality. As such, such a strong effect of metformin seems unlikely and the results of this prior radiation study should be interpreted with caution.

While our study was certainly limited by small numbers and short follow-up, we saw no benefit of metformin use for improving oncologic outcomes in PC patients following RP. In fact, our exploratory analysis suggested that higher metformin dose may even increase risk of CRPC, distant metastases and PC-specific mortality, although again our numbers were too small to conduct multivariable analysis or draw firm conclusions. These exploratory findings must be interpreted with caution as higher metformin dose may reflect an effort to improve poor diabetes control. Indeed, we found that HbA1c levels were significantly elevated in patients receiving higher doses of metformin. However, there is currently no evidence to suggest that poor diabetes control is associated with worse PC-specific long-term outcomes. Of note, we previously reported in this same patient cohort that while elevated HbA1c levels among patients with diabetes were associated with higher pathologic Gleason score, there was no association of HbA1c levels with BCR. In this analysis, adjusting our results for HbA1c levels did not alter our findings. Therefore, this suggestion of a dose-dependent effect of metformin on worsening long-term PC-specific outcomes may merit further investigation. The effect of metformin on lowering insulin levels may, to some extent, mirror the lower insulin environment of long-standing diabetes. In other words, metformin users and individuals with long-standing diabetes may have lower insulin levels than diabetic metformin non-users and diabetes-free individuals, respectively. We speculate that this lower insulin environment, while it may reduce overall PC incidence, may also select for more aggressive, growth factor-independent PC. Indeed, epidemiologic evidence suggests that, despite the protective effect of longer term diabetes (>5 years) on overall PC risk, longer duration of diabetes was found to significantly increase the risk of metastasis following RP. As such, these data support the hypothesis that PC tumors which can survive and grow in a lower insulin environment are more aggressive, though this remains speculative. Of note, metformin users, particularly those on high metformin doses, had significantly longer duration of diabetes that may present a potential source of bias in this study, although adjusting our models for duration of diabetes did not alter our results.

This study has several limitations that must be considered. We could not assess use of other diabetic medications including insulin, sulfonylureas or thiazolidinediones. We used the earliest issue date for metformin to estimate duration of use, but we could not confirm whether patients took metformin continuously from the earliest issue date to RP. Furthermore, it is possible that some metformin non-users became metformin users after RP but before BCR. Given our hypothesis that metformin use delays BCR, this may bias our results toward the null. Future studies are required to assess the potential impact of post-operative metformin use on BCR. Neither could we definitively distinguish type I from type II diabetes, however, median age of diabetes diagnosis was 57 years old, and thus the majority are likely to be type II diabetic patients. As with all observational epidemiologic studies of drug effects, our study may be subject to confounding by indication, as allocation of treatment was not randomized and thus may differ by risk profile of the patient. However, a study strength was near complete BMI and HbA1c data for 90 and 75% of patients, respectively. We were therefore able to confirm that neither BMI nor diabetes control differed significantly when patients were stratified by metformin use, thus addressing these potentially confounding factors to the greatest extent possible in this retrospective cohort study. One final point to consider is that the median duration of metformin use in this study was 26 months, with the majority of men using metformin for <4 years. Whether this is sufficient time for metformin to have an impact on PC outcomes remains unknown.
In conclusion, observational epidemiologic evidence supporting a role for metformin in PC prevention and treatment is weak. Our retrospective cohort analysis found no effect of metformin use on BCR in an RP cohort of PC patients with diabetes. Further exploratory analysis found a suggestion that higher metformin dose, vs metformin non-use, increased the risk of CRPC, metastases and...

Table 2. Demographic, clinical and pathological features of metformin users and non-users according to metformin dose

| Metformin dose pre-surgery | None (n = 215) | Low dose (< 2000 mg/day; n = 83) | High dose (≥ 2000 mg/day; n = 73) |
|---------------------------|---------------|----------------------------------|-----------------------------------|
| Age at surgery, mean (s.d.) | 62.2 (5.8)    | 62.0 (5.3)                       | 61.0 (6.2)                       |
| Months follow-up, median (IQR) | 73 (45–110) | 60 (39–82)                       | 58 (31–78)                       |

Race, n (%) | White 98 (45.6) 38 (45.8) 39 (53.4) 0.639d | Black 103 (47.9) 42 (50.6) 31 (42.4) | Non-white-non-black 14 (6.5) 3 (3.6) 3 (4.1) |
Year of surgery, median (IQR) | 2002 (1998–2006) 2005 (2003–2007) 2006 (2003–2007) 0.0001c |

BMI, n (%) | ≤ 24.9 kg m⁻² 24 (12.8) 10 (12.5) 5 (6.9) 0.764d | 25.0–29.9 kg m⁻² 76 (40.6) 36 (45.0) 33 (45.2) | ≥ 35.0 kg m⁻² 63 (33.7) 22 (27.5) 23 (31.5) |
Duration of diabetes (months), median (IQR) | 37 (10–86) 46 (21–78) 68 (37–104) 0.027c |
Duration metformin use (months), median (IQR) | NA 21 (7–38) 37 (18–52) 0.0001c |
% HbA1c, median (IQR) | 6.8 (6.2–8.0) 6.7 (6.0–7.6) 7.7 (6.4–8.5) 0.020c |
Pre-operative PSA, median (IQR) | 6.5 (4.7–10.2) 5.9 (4.8–9.4) 5.3 (4.6–7.5) 0.094c |

| Biochemical Gleason sum, n (%) | Pathological Gleason Sum, n (%) |
|------------------------------|-------------------------------|
| 2–6                          | Path. Gleason 7 v s < 7       |
| 2–6                          | Extraprostatic extension, n (%) |
| 2–6                          | Lymph-node metastases, n (%)  |

| Pathological Gleason Sum, n (%) | Path. Gleason 7 v s < 7 |
|-------------------------------|-------------------------|
| 2–6                           | 1.03 (0.58–1.83)         |
| 7                             | 1.03 (0.58–1.83)         |
| 8–10                          | 1.03 (0.58–1.83)         |

| Positive margins             | HR (95% CI) | P |
|------------------------------|-------------|---|
| Path. Gleason 7 v s < 7      | 1.03 (0.58–1.83) | 0.920 |
| Extraprostatic extension     | 1.73 (0.93–3.22) | 0.082 |
| Seminal vesicle invasion     | 0.95 (0.40–2.30) | 0.917 |
| Positive margins             | 1.14 (0.70–1.87) | 0.588 |

Abbreviations: BMI, body mass index; HbA1c, glycosylated hemoglobin; IQR, interquartile range.
*p-values computed using ANOVA, χ², and Kruskal-Wallis.
**p-values computed using ANOVA.
***p-values computed using Kruskal-Wallis.
****p-values computed using χ².
Bold indicates significant P value (P < 0.05).

Table 3. Risk of adverse pathological features by metformin use, dose and duration of use

| Use (n = 145) vs non-use (n = 181) | Low dose (n = 74) vs non-use (n = 181) | High dose (n = 43) vs non-use (n = 181) | Months of use (among users; n = 145) |
|-----------------------------------|---------------------------------------|----------------------------------------|-------------------------------------|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| Path. Gleason 7 v s < 7           | 1.03 (0.58–1.83) | 0.920 | 0.83 (0.42–1.64) | 0.585 | 1.32 (0.63–2.76) | 0.457 | 0.99 (0.96–1.01) | 0.167 |
| Extraprostatic extension          | 1.73 (0.93–3.22) | 0.082 | 1.72 (0.82–3.60) | 0.152 | 1.75 (0.82–3.75) | 0.149 | 1.00 (0.98–1.02) | 0.680 |
| Seminal vesicle invasion          | 0.95 (0.40–2.30) | 0.917 | 0.13 (0.02–1.05) | 0.055 | 2.32 (0.88–6.13) | 0.088 | 0.99 (0.95–1.03) | 0.607 |
| Positive margins                  | 1.14 (0.70–1.87) | 0.588 | 1.11 (0.61–2.02) | 0.736 | 1.18 (0.65–2.16) | 0.586 | 1.00 (0.99–1.02) | 0.675 |

Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio.
P-values computed using multivariable logistic regression and adjusted for clinical features: age at surgery, year of surgery, BMI, race, pre-operative PSA, surgical center, biopsy Gleason score and clinical stage.
PC-specific mortality. Future prospective studies and ultimately randomized controlled trials are required to establish whether there is any role for metformin in PC oncological management.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This study was supported by EHA: NCI SR25-CA126938-03; SJF: NIH Grant 1-R01-CA131235-01A1 and NIH 1K24CA160653.

REFERENCES
1 Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Bray F, Parkin DM. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–1092.
2 Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31–40.
3 Kaspr JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124: 1388–1403.
4 Zhang Y, Yang Y, Skrip H, Hu D, Wang Y, Wong C et al. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 2012; 49(Suppl 1): S233–S246.
5 Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304–1305.
6 Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabet Care 2009; 32: 1620–1625.
7 Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010; 3: 1451–1461.
8 Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813–822.
9 Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254–258.
10 Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012; 35: 299–304.
11 Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The anti-diabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576–3586.
12 Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71: 4366–4372.
13 Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Res (Phila) 2008; 1: 369–375.
14 Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic body mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039–1047.
15 Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617–1622.
16 Murtola T, Tammeila T, Lahetla J, Auvinnen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 2008; 168: 925–931.
17 Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–1777.
18 Azuayi L, Dell’Aniello S, Gagnon B, Pollak M, Sissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011; 20: 337–344.
19 Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010; 76: 1240–1244.

Table 4. Risk of biochemical recurrence by metformin use, dose and duration of use

| Use (n = 155) vs non-use (n = 214) | Low dose (n = 83) vs non-use (n = 214) | High dose (n = 72) vs non-use (n = 214) | Months of use (among users; n = 155) |
|----------------------------------|----------------------------------------|----------------------------------------|--------------------------------------|
| HR (95% CI)                      | P                                      | HR (95% CI)                            | P                                     |
| Crude                            | 0.86 (0.61–1.23)                       | 0.78 (0.49–1.22)                       | 0.276                                 |
| Model 1*                         | 1.01 (0.67–1.52)                       | 0.92 (0.56–1.54)                       | 0.759                                 |
| Model 2                          | 0.93 (0.61–1.41)                       | 0.90 (0.53–1.53)                       | 0.691                                 |

Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio.
*Adjusted for clinical features: age at surgery, year of surgery, BMI, race, pre-operative PSA, surgical center, biopsy Gleason score and clinical stage.
†Adjusted for clinical and pathologic features: age at surgery, year of surgery, BMI, race, pre-operative PSA, surgical center, clinical stage, pathological Gleason score, extracapsular extension, seminal vesicle invasion and positive surgical margins.

Table 5. Risk of long-term outcomes by metformin use, dose and duration of use

| Use (n = 156) vs non-use (n = 215) | Low dose (n = 83) vs non-use (n = 215) | High dose (n = 73) vs non-use (n = 215) | Months of use (among users; n = 156) |
|----------------------------------|----------------------------------------|----------------------------------------|--------------------------------------|
| HR (95% CI)                      | P                                      | HR (95% CI)                            | P                                     |
| CRPC                             | 2.98 (0.98–9.05)                       | 0.054                                  | 1.22 (0.23–6.33)                      |
| Metastasis                       | 2.53 (0.70–9.22)                       | 0.158                                  | 0.78 (0.09–7.06)                      |
| PC-specific death                | 2.89 (0.68–12.33)                      | 0.150                                  | 1.08 (0.11–10.47)                     |

Abbreviations: CI, confidence interval; CRPC, castrate-resistant prostate cancer; HR, hazard ratio; PC, prostate cancer.
P-values computed using Cox proportional hazard analysis. Limited number of events precluded multivariable analysis; however, when clinical and pathologic features were added to the unadjusted model one at a time, no variable markedly altered the hazard ratio for these distant outcomes.
20 Kaushik D, Kames RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2013.
21 Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, MJ. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2012; 63: 709–716.
22 Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti Jr. JC et al. Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Prostate Cancer Prostatic Dis 2011; 14: 361–366.
23 Wu C, Aronson WJ, Terris MK, Presti Jr. JC, Kane CJ, Amling CL et al. Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU Int 2013; 111: E310–E318.
24 Scher HI, Halabi S, Tannock I, Morris M, Stemberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–1159.
25 Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367: 203–213.
26 Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708–1717.
27 Kim HS, Presti Jr. JC, Aronson WJ, Terris MK, Kane CJ, Amling CL et al. Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 2010; 70: 1540–1546.